

Regimen Reference Order – HEME – azaCITIDine (MDS)

ARIA: HEME – [azaCITIDine (MDS)]

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 28 days)

Indication for Use: Myelodysplastic Syndrome

CVAD: Not Required

Proceed with treatment if:

Cycles 1 to 4

- *Proceed with treatment regardless of ANC and platelet value if the patient is feeling well (no signs or symptoms of infection)*

Cycle 5 and Onwards

- *ANC equal to or greater than $0.5 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$*
- ❖ *Consult Hematologist if parameters not met*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – HEME – azaCITIDine (MDS)

Drug	Dose	CCMB Administration Guideline
Days 1 to 7		
ondansetron	8 mg	Orally 30 minutes before each dose of azaCITIDine
azaCITIDine	75 mg/m ²	Subcutaneous into abdomen * Alert: Maximum volume at each injection site is 4 mL * Nursing Alert: Air sandwich technique is recommended for administration
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See HEME DSG – Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

Prior to each Cycle

- CBC, serum creatinine, urea, electrolytes and liver enzymes as per Physician Orders

Recommended Support Medications		
Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Instruct patient to report to clinic if they are experiencing injection site reactions that are bothersome
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of azaCITIDine

ADDITIONAL INFORMATION

- Due to limited room temperature stability, azaCITIDine MUST be stored in fridge until immediately prior to administration. DO NOT store at room temperature unless otherwise indicated by pharmacy
- All 7 doses of azaCITIDine must be administered within a 10-day period if not given consecutively